What is he best known for?
The fields of study he is best known for:
- Gene
- Internal medicine
- Cancer
His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Surgery and Pathology.
His biological study spans a wide range of topics, including Fluorescence in situ hybridization, Transplantation and Cytogenetics.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Cancer research.
His Oncology research includes themes of Cancer, Survival rate, Immunology, Disease and Survival analysis.
His work in Surgery addresses subjects such as Urology, which are connected to disciplines such as Randomized controlled trial.
Hervé Avet-Loiseau has researched Pathology in several fields, including Stage and Immunophenotyping.
His most cited work include:
- International staging system for multiple myeloma. (1912 citations)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma (795 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Multiple myeloma, Internal medicine, Oncology, Cancer research and Lenalidomide.
His Multiple myeloma study integrates concerns from other disciplines, such as Surgery, Transplantation and Pathology.
His Pathology study combines topics in areas such as Fluorescence in situ hybridization and Cytogenetics.
His studies link Gastroenterology with Internal medicine.
Hervé Avet-Loiseau combines subjects such as Survival rate, Newly diagnosed, Daratumumab, Minimal residual disease and Hazard ratio with his study of Oncology.
His work deals with themes such as Cell culture, Gene expression, Gene, Gene expression profiling and Bone marrow, which intersect with Cancer research.
He most often published in these fields:
- Multiple myeloma (67.59%)
- Internal medicine (43.28%)
- Oncology (27.99%)
What were the highlights of his more recent work (between 2019-2021)?
- Multiple myeloma (67.59%)
- Internal medicine (43.28%)
- Oncology (27.99%)
In recent papers he was focusing on the following fields of study:
Hervé Avet-Loiseau mainly focuses on Multiple myeloma, Internal medicine, Oncology, Cancer research and Daratumumab.
His Multiple myeloma research is multidisciplinary, incorporating perspectives in Progression-free survival, MEDLINE, Minimal residual disease, Disease and Computational biology.
His research integrates issues of Clinical efficacy, Response to treatment and Cytogenetics in his study of Minimal residual disease.
His Oncology research incorporates elements of Cancer, Newly diagnosed, Fluorescence in situ hybridization and Hazard ratio.
Hervé Avet-Loiseau has included themes like Immune checkpoint, Enhancer, Transcriptome, Gene expression and Profiling in his Cancer research study.
Hervé Avet-Loiseau works mostly in the field of Daratumumab, limiting it down to concerns involving CD38 and, occasionally, Receptor, Immune system and CD8.
Between 2019 and 2021, his most popular works were:
- Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). (38 citations)
- Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. (20 citations)
- Revealing the impact of structural variants in multiple myeloma (15 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Hervé Avet-Loiseau focuses on Multiple myeloma, Internal medicine, Oncology, Daratumumab and Minimal residual disease.
His work carried out in the field of Multiple myeloma brings together such families of science as MEDLINE, Disease, Gene, Varicella zoster virus and Computational biology.
Internal medicine and Chromosome 17 are commonly linked in his work.
His research in the fields of Autologous transplant overlaps with other disciplines such as Extremely Poor.
His Daratumumab research is multidisciplinary, incorporating elements of Pharmacology, Transplantation and Intensive care medicine.
His research in Minimal residual disease intersects with topics in Meta-analysis, Progression-free survival and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
